Pipeline news

• Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

  11 November 2020

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update on key initiatives.

• Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan

  06 November 2020

  

  Atea Pharmaceuticals, Inc.  (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of itsAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the appointment of Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee. common stock at a price to the public of  $24.00  per share.

• Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update

  02 November 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended  September 30, 2020 . In addition, the Company provided a clinical and business update.

• Atea Pharmaceuticals Announces Pricing of Initial Public Offering

  29 October 2020

  

  Atea Pharmaceuticals, Inc.  (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price to the public of  $24.00  per share.

• Epic Sciences and Predicine Jointly Announce Strategic Partnership to Expand Liquid Biopsy Offerings to Biopharmaceutical Partners

  29 October 2020

  

  Epic Sciences, Inc. and Predicine, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing.

• College health insurer Wellfleet teams up with binx health to keep students safe and campuses open in the fight against COVID-19

  27 October 2020

  

  Wellfleet Insurance has teamed up with binx health to offer college clients access to easy at-home/in-dorm sample collection for COVID-19 testing using binx’s enterprise solutions for population health screening.

• FDA Grants EUAs for Wren Labs, P23 Coronavirus Tests, Binx Health At-Home Sample Collection Kit

  26 October 2020 genomeweb

  

  The US Food and Drug Administration on Tuesday reissued Emergency Use Authorizations for SARS-CoV-2 tests developed by Wren Laboratories and P23 Labs to allow their use with new specimen types, and granted EUA to Binx Health's SARS-CoV-2 at-home nasal swab collection kit.

• Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19

  22 October 2020

  

  Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announces that the company has entered into an agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the exclusive rights to research, develop and distribute AT-527 as an oral antiviral treatment for COVID-19 in territories outside of the United States. Under the terms of the agreement, Atea will receive an upfront payment of $350 million in cash from Roche with the potential for future milestone payments and royalties.

• Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)

  24 September 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has satisfied the FDA’s protocol-specific questions for the registrational Phase 3 trial (the RAISE trial) in refractory status epilepticus (RSE), allowing the company to begin enrollment in this clinical trial.

• Atea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors

  14 September 2020

  

  Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next- generation therapeutics for severe viral infections, today announced the appointment of Polly Murphy, D.V.M., Ph.D., Chief Business Officer of UroGen Pharma, to its Board of Directors. Dr. Murphy is a seasoned pharmaceutical executive with a wide range of experience spanning research and development, strategy and operations.